Cellebrite DI (NASDAQ: CLBT) has reduced its full-year sales guidance for FY2026, signaling a more conservative outlook on revenue generation. The company revised its projected sales range downward from $565 million to $571 million to a new band of $555 million to $561 million. This adjustment places the updated guidance below the market consensus estimate of $568.048 million, suggesting that near-term operational or market factors may be constraining top-line growth relative to prior expectations.

The revision reflects a narrowing of the upper end of the forecast by $10 million and a reduction in the lower bound by $10 million, maintaining a consistent range width of $6 million while shifting the entire outlook lower. With the midpoint of the new guidance sitting at $558 million, the company is now projecting revenues approximately $10 million below the analyst consensus.

What the Numbers Show

The divergence between the revised guidance midpoint ($558 million) and the analyst estimate ($568.048 million) highlights a significant miss against market expectations. This gap of roughly $10 million suggests that either order conversion rates have softened or macroeconomic pressures are impacting deal closures more than previously anticipated. The uniform $10 million cut across both the floor and ceiling of the guidance range indicates a systematic adjustment rather than a change in volatility or risk profile.

This downward revision serves as a key indicator for investors monitoring Cellebrite’s ability to sustain its growth trajectory in the digital intelligence sector. The failure to meet the consensus estimate may prompt a reassessment of valuation multiples if the underlying drivers of this slowdown persist into subsequent quarters.